Know Labs has announced the launch of KnowU, its latest wearable non-invasive continuous glucose monitor (CGM).

The device enhances the user experience with features such as a rechargeable battery and a companion mobile app.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The KnowU represents the culmination of an eight-month accelerated development process. An initial prototype was released in June 2023.

The device integrates a proprietary sensor, which has demonstrated stability and accuracy in a laboratory setting and is now miniaturised for wearable use.

Designed for versatility, the KnowU can be attached to the body using an adhesive or worn on the wrist or forearm with a strap.

It is significantly more compact and lighter than its predecessor and has onboard computing power and machine-learning capabilities.

The device, which is set to undergo FDA clinical trials, will focus on collecting extensive data to assess the technology’s performance over continuous wear, across various body locations and within broader glycemic ranges in diverse populations.

It operates on the principle of dielectric spectroscopy, utilising an RF sensor to measure glucose levels.

Know Labs plans to conduct large-scale external clinical trials this year, during which it will continue to refine the KnowU device and its algorithms.

Know Labs CEO and chairman Ron Erickson said: “The prevalence of diabetes is growing globally at an alarming rate. Millions of people face significant barriers in accessing the technology and treatment they need to effectively manage their diabetes.

“Know Labs is committed to delivering an accessible, affordable and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes.

“The KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”

Last year, Know Labs announced plans to release the first commercially available non-invasive glucose monitor with the launch of its Generation 1 device.